

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10510411	
	Filing Date		2005-09-12	
	First Named Inventor	Habib Zaghouani et al.		
	Art Unit	1644		
	Examiner Name	Gerald R. Ewoldt		
Attorney Docket Number		119742-002		

U.S. PATENTS						Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button.

Add

U.S. PATENT APPLICATION PUBLICATIONS						Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button.

Add

FOREIGN PATENT DOCUMENTS							Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² j	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1	9932136	WO		1999-07-01	Alexion Pharmaceuticals, Inc.		<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button.

Add

NON-PATENT LITERATURE DOCUMENTS		Remove	
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵

- 1 Aitkinson, Mark A. et al., the NOD Mouse Model of Type 1 Nature Medicine. June 1999. 5(6) 601-604.
- 2 Boitard, C., et al., Peripherin: An islet antigen that is cross-reactive with nonobese diabetic mouse class II gene products. Jan. 1992. Proc. Natl. Acad. Sci. 89:172-176.
- 3 Gregg, R. et al. Modulation of diabetogenic T cells by an Ig-chimera expressing insulin B 9-12. 2000. Faseb Journal & Joint Annual Meeting of the American Association of Immunologists and the Clinical Immunology Society, Seattle Washington, May 12-16, 2000. 14(6):A1218.
- 4 Gregg, R. et al. A plausible multi-modal strategy for effective suppression of diabetes. 2002. Faseb Journal, Bethesda, US, 22 March 2002. pp. A1043.
- 5 Johnson, G.G., et al. 1999. Anti-CD43 Monoclonal antibody L11 Blocks Migration of T Cells to Inflamed Pancreatic Islets and Prevents Development of Diabetes in Nonobese Diabetic Mice. The Journal of Immunology. 163:5678-5685.
- 6 Kürschner, C. et al. 1992. "IFN-gamma receptor-ig fusion proteins half-life, immunogenicity, and in vivo activity." Journal of Immunology, The Williams and Wilkins Co., Baltimore, vol. 149, no. 12, 15 December 1992. pp.4096-4100
- 7 Lenschow D.J. et al. 1992. "Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4LG." Science, Washington, D.C., vol. 257, no. 5071, 7 August 1992. pp. 789-792.
- 8 Skyler, J.S. et al., 2005. "Effects of oral insulin in relatives with type1 diabetes. Diabetes Care. 28(5):1068-1076.
- 9 Zheng, X. et al. 1999. "IL-2 receptor-targeted cytolytic IL-2/Fx fusion protein treatment blocks diabetogenic autoimmunity in nonobese diabetic mice." Journal of Immunology, the Williams nad Wilkins Co., Baltimore, vol. 163, no. 7, 1 October 1999. pp. 4041-4048.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10510411
Filing Date	2005-09-12
First Named Inventor	Habib Zaghouani et al.
Art Unit	1644
Examiner Name	Gerald R. Ewoldt
Attorney Docket Number	119742-002

12	Sutterwala, F S. et al. 1998. Reversal of proinflammatory responses by ligating the macrophage Fcg receptor type I. J. Exp. Med. 188:217-222.	<input type="checkbox"/>
----	---	--------------------------

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.